Lion Biotechnologies Inc. (NASDAQ:LBIO)‘s stock had its “buy” rating reiterated by research analysts at Roth Capital in a research note issued on Monday. They presently have a $15.00 target price on the biotechnology company’s stock. Roth Capital’s price target suggests a potential upside of 112.77% from the stock’s current price.
Several other brokerages also recently weighed in on LBIO. Chardan Capital set a $20.00 price objective on Lion Biotechnologies and gave the company a “buy” rating in a research report on Sunday, August 21st. Zacks Investment Research downgraded Lion Biotechnologies from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. Jefferies Group reiterated a “buy” rating and issued a $13.00 price objective on shares of Lion Biotechnologies in a research report on Monday, November 7th. Finally, Cowen and Company reiterated a “buy” rating on shares of Lion Biotechnologies in a research report on Friday, November 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Lion Biotechnologies has an average rating of “Buy” and a consensus target price of $18.29.
Lion Biotechnologies (NASDAQ:LBIO) traded down 5.44% during mid-day trading on Monday, reaching $6.95. 225,055 shares of the company traded hands. The stock’s market capitalization is $431.50 million. The company’s 50-day moving average is $6.76 and its 200-day moving average is $7.58. Lion Biotechnologies has a 12-month low of $4.24 and a 12-month high of $9.58.
Several institutional investors have recently made changes to their positions in LBIO. KCG Holdings Inc. acquired a new position in shares of Lion Biotechnologies during the third quarter worth approximately $101,000. Quantitative Investment Management LLC purchased a new stake in shares of Lion Biotechnologies during the second quarter valued at $117,000. Stevens Capital Management LP purchased a new stake in shares of Lion Biotechnologies during the third quarter valued at $118,000. TD Asset Management Inc. purchased a new stake in shares of Lion Biotechnologies during the third quarter valued at $123,000. Finally, Geduld E E boosted its stake in shares of Lion Biotechnologies by 50.0% in the third quarter. Geduld E E now owns 15,000 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 79.62% of the company’s stock.
Lion Biotechnologies Company Profile